How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,055 results for

Deep Vein Thrombosis of the Upper Extremity

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1041. Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

-20. An adapted version of the Rotterdam Symptom Checklist will be used to specifically assess patients with thrombosis. Patients will complete these two instruments at study entry, day 3, day 5 and at the end of study if different from day 5. Condition or disease Intervention/treatment Phase Neoplasms Deep Vein Thrombosis Drug: Dalteparin (Fragmin) Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 26 participants (...) . Patients eligible for the study will include: Patients with solid tumors (including lymphoma and myeloma). Patients with clinical and venographic or ultrasonographic evidence of thrombosis of the proximal or distal lower or upper extremity. Patients with catheter-related thrombosis will be eligible for the study if they are not candidates for thrombolytic therapy. Patients with Zubrod performance status of <2. (Appendix A) Patients with adequate bone marrow function: platelets >100,000/mm3, and ANC

2002 Clinical Trials

1042. Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis

Intervention/treatment Phase Deep Vein Thrombosis Device: OmniWave Endovascular System Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Study Start (...) , 2008 Last Verified: March 2008 Keywords provided by OmniSonics Medical Technologies, Inc.: DVT Peripheral Vascular Disease Venous Thrombosis Deep Vein Thrombosis Additional relevant MeSH terms: Layout table for MeSH terms Thrombosis Venous Thrombosis Upper Extremity Deep Vein Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases

2008 Clinical Trials

1043. The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00216866 Recruitment Status : Completed First Posted : September 22, 2005 Last Update Posted : August 28, 2017 Sponsor: Lawson Health Research Institute Collaborator: Pfizer Information provided by (Responsible Party): Lawson Health Research Institute Study Details Study Description Go to Brief Summary: The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein (...) thrombosis (UEDVT) in patients treated with dalteparin and warfarin. Anticoagulation with dalteparin and warfarin in patients with UEDVT secondary to central venous catheters in patients with an active malignancy is an effective therapy as quantified by the success of catheter preservation. A prolonged line salvage rate without a recurrence of UEDVT will improve the management of cancer patients who develop upper extremity deep venous thrombosis in the setting of a central venous (CV) catheter. Condition

2005 Clinical Trials

1044. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review

Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review Mustafa B O, Rathbun S W, Whitsett T L, Raskob G E Authors' objectives To determine the sensitivity and specificity (...) of ultrasonography in the diagnosis of upper extremity deep vein thrombosis (DVT), and to determine the safety of withholding anticoagulant therapy in patients with negative ultrasonography results. Searching MEDLINE was searched from January 1980 to December 2000 using the MeSH terms 'upper extremity' and 'thrombosis'. In addition, the bibliographies of the retrieved articles were examined. Only studies reported in the English language were included. Study selection Study designs of evaluations included

2002 DARE.

1045. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. (Abstract)

to the femoral access site developed lower extremity deep vein thrombosis (p = .02). In addition, seven (29%) patients randomized to the lower access site sustained non-diagnostic ultrasound examinations. A total of 13 (54%) of 24 patients from the lower access group developed abnormal ultrasound examinations (p < .001). Age, duration of catheterization, coagulation profile, deep vein thrombosis prophylaxis, and Acute Physiology and Chronic Health Evaluation II scores were similar between the upper and lower (...) Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. To determine the frequency of central venous catheter-induced deep vein thrombosis of the femoral vein.Prospective, randomized, controlled trial.Tertiary care center.Forty-five patients in a medical-surgical intensive care unit who required central venous catheterization.Patients were randomized to receive central venous catheterization in either upper (subclavian

1995 Critical care medicine Controlled trial quality: uncertain

1046. Treatment of Upper Extremity Deep-Vein Thrombosis

Treatment of Upper Extremity Deep-Vein Thrombosis Treatment of Upper Extremity Deep-Vein Thrombosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Upper Extremity Deep-Vein Thrombosis (...) Rathbun, University of Oklahoma Study Details Study Description Go to Brief Summary: The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months. Condition or disease Intervention/treatment Phase Deep-Vein Thrombosis Drug: Dalteparin sodium injection Drug: Warfarin Phase 4 Detailed Description: Upper extremity deep-vein thrombosis (DVT

2005 Clinical Trials

1047. Upper-extremity deep-vein thrombosis in an elderly man Full Text available with Trip Pro

Upper-extremity deep-vein thrombosis in an elderly man 17420489 2007 05 09 2018 11 13 1488-2329 176 8 2007 Apr 10 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Upper-extremity deep-vein thrombosis in an elderly man. 1078-9 Har-Noy Ofir O Department of Internal Medicine, Chaim Sheba Medical Center, Tel-Hashomer, Israel. Meltzer Eyal E eng Case Reports Journal Article Canada CMAJ 9711805 0820-3946 0 Anticoagulants 0 Enoxaparin 0 factor V Leiden (...) 5Q7ZVV76EI Warfarin 9001-24-5 Factor V EC 1.5.1.20 Methylenetetrahydrofolate Reductase (NADPH2) AIM IM Aged Anticoagulants therapeutic use Arm blood supply Chest Pain etiology Dyspnea etiology Edema etiology Enoxaparin therapeutic use Exercise Factor V genetics Humans Male Methylenetetrahydrofolate Reductase (NADPH2) genetics Mutation Ultrasonography, Doppler Venous Thrombosis diagnosis drug therapy Warfarin therapeutic use 2007 4 11 9 0 2007 5 10 9 0 2007 4 11 9 0 ppublish 17420489 176/8/1078 10.1503

2007 CMAJ : Canadian Medical Association Journal

1048. Upper extremity deep vein thrombosis: a community-based perspective. Full Text available with Trip Pro

Upper extremity deep vein thrombosis: a community-based perspective. The purpose of this study was to examine the magnitude, risk factors, management strategies, and outcomes in a population-based investigation of patients with upper, as compared with lower, extremity deep vein thrombosis diagnosed in 1999.The medical records of all residents from Worcester, Massachusetts (2000 census=478,000) diagnosed with ICD-9 codes consistent with possible deep vein thrombosis at all Worcester hospitals (...) during 1999 were reviewed and validated.The age-adjusted attack rate (per 100,000 population) of upper extremity deep vein thrombosis was 16 (95% confidence interval [CI], 13-20) compared with 91 (95% CI, 83-100) for lower extremity deep vein thrombosis. Patients with upper extremity deep vein thrombosis were significantly more likely to have undergone recent central line placement, a cardiac procedure, or an intensive care unit admission than patients with lower extremity deep vein thrombosis

2007 American Journal of Medicine

1049. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Full Text available with Trip Pro

Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. One third of cases of upper-extremity deep vein thrombosis (DVT) are primary, ie, they occur in the absence of central venous catheters or cancer. Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown.We studied 115 primary upper-extremity DVT patients and 797 healthy controls for the presence of thrombophilia due to factor V Leiden, prothrombin G20210A (...) , antithrombin, protein C, protein S deficiency, and hyperhomocysteinemia. Transient risk factors for venous thromboembolism were recorded. Recurrent upper-extremity DVT was evaluated prospectively over a median of 5.1 years of follow-up. The adjusted odds ratio for upper-extremity DVT was 6.2 (95% CI 2.5 to 15.7) for factor V Leiden, 5.0 (95% CI 2.0 to 12.2) for prothrombin G20210A, and 4.9 (95% CI 1.1 to 22.0) for the anticoagulant protein deficiencies. Hyperhomocysteinemia and oral contraceptives were

2004 Circulation

1050. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Full Text available with Trip Pro

Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Upper-extremity deep vein thrombosis (UEDVT) occurs spontaneously or sometimes develops as a complication of pacemaker use, long-term use of a central venous catheter (CVC), or cancer.To improve our understanding of UEDVT, we compared the demographics, symptoms, risk factors, prophylaxis, and initial management of 324 (6%) patients with central venous catheter (CVC)-associated UEDVT, 268 (5%) patients with non-CVC (...) -associated UEDVT, and 4796 (89%) patients with lower-extremity DVT from a prospective US multicenter DVT registry. The non-CVC-associated UEDVT patients were younger (59.2+/-18.2 versus 64.2+/-16.9 years old; P<0.0001), less often white (65% versus 73%; P<0.01), leaner (body mass index [BMI] 26.8+/-7.1 versus 28.5+/-7.3 kg/m2; P<0.001), and more likely to smoke (19% versus 13%; P=0.02) than the lower-extremity DVT patients. By way of propensity analysis and multivariable logistic regression analysis, we

2004 Circulation

1051. Clinical outcome of patients with upper-extremity deep vein thrombosis: Results from the RIETE Registry. Full Text available with Trip Pro

Clinical outcome of patients with upper-extremity deep vein thrombosis: Results from the RIETE Registry. There is little information on the clinical outcome of patients with upper-extremity deep vein thrombosis (DVT).RIETE is an ongoing registry of consecutive patients with objectively confirmed, symptomatic, acute DVT or pulmonary embolism (PE). In this analysis, we analyzed the demographic characteristics, treatment, and 3-month outcome of all patients with DVT in the arm.Of the 11,564 DVT

2007 Chest

1052. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). (Abstract)

Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Central venous access devices are often essential for the administration of chemotherapy to patients with malignancy, but its use has been associated with a number of complications, mainly thrombosis. The true incidence of upper extremity deep vein thrombosis (DVT) in this setting is difficult to estimate since there are very few studies in which DVT

1996 Thrombosis and haemostasis Controlled trial quality: uncertain

1053. Upper extremity deep venous thrombosis. (Abstract)

Upper extremity deep venous thrombosis. To determine the prevalence of symptomatic upper extremity deep venous thrombosis (DVT) and its association with symptomatic acute pulmonary embolism (PE) in a community teaching hospital.The prevalence of symptomatic upper extremity DVT was evaluated retrospectively at a community teaching hospital during the 2-year period between July 1, 1998, and June 30, 2000. Patients were identified by International Classification of Disease, ninth revision (...) , clinical modification, discharge codes and a review of the records of all compression Doppler ultrasonograms, venograms of the upper extremities, and magnetic resonance angiograms of the upper extremities.Symptomatic upper extremity DVT was diagnosed in 65 of 44,136 patients of all ages (0.15%) [or 64 of 34,567 adult patients >or= 20 years of age; 0.19%]. In seven patients, the upper extremity DVT was shown by venography to extend proximally to the brachiocephalic vein. Among these, the DVT extended

2003 Chest

1054. A combination of heparin and an intermittent pneumatic compression device may be more effective to prevent deep-vein thrombosis in the lower extremities after laparoscopic cholecystectomy. (Abstract)

A combination of heparin and an intermittent pneumatic compression device may be more effective to prevent deep-vein thrombosis in the lower extremities after laparoscopic cholecystectomy. The purpose of this study was to clarify the effect of a combination of heparin and an intermittent pneumatic compression device on thrombogenesis and platelet activation in the upper and lower extremities after laparoscopy.A blinded study was performed on 30 patients. Patients were randomly injected (...) in the PSS group increased significantly 24 h after surgery.A combination of low-molecular-weight heparin and intermittent pneumatic compression may be more effective to prevent deep-vein thrombosis in the legs.

2002 Surgical endoscopy Controlled trial quality: uncertain

1055. Upper extremity deep vein thrombosis associated with indwelling peripheral venous catheters in gynecology oncology patients. (Abstract)

Upper extremity deep vein thrombosis associated with indwelling peripheral venous catheters in gynecology oncology patients. The goal of this study was to review the clinical presentation, management, and outcome of upper extremity deep vein thrombosis (UEDVT) in women with gynecologic malignancies who had indwelling peripheral venous access catheters.From a retrospective review of medical records, we identified 13 patients with various gynecologic malignancies who were diagnosed with UEDVT (...) = 1). Diagnosis of thrombosis was confirmed using Doppler ultrasound (n = 4), venography (n = 5), and both modalities (n = 4). Management of UEDVT consisted of anticoagulation with warfarin (2-6 months) (n = 9), urokinase infusion (n = 2), intravenous antibiotics for 21 days and heparin for 10 days (n = 1), arm elevation only (n = 1), Lovenox for 60 days (n = 1), and no therapy (n = 1). There were no complications associated with anticoagulation. No patient had a pulmonary embolism. The incidence

2003 Gynecologic Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>